Oxford Biomedica (LON:OXB) Sets New 1-Year High – Here’s Why

Shares of Oxford Biomedica plc (LON:OXB) reached a new 52-week high on Thursday . The stock traded as high as GBX 512 ($6.89) and last traded at GBX 507.05 ($6.82), with a volume of 130906 shares. The stock had previously closed at GBX 505 ($6.79).

Analysts Set New Price Targets

OXB has been the subject of several research analyst reports. JPMorgan Chase & Co. reduced their price objective on shares of Oxford Biomedica from GBX 490 to GBX 400 and set a “neutral” rating for the company in a report on Tuesday, July 15th. Peel Hunt reissued a “buy” rating and issued a GBX 451 price target on shares of Oxford Biomedica in a report on Friday, August 1st. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Oxford Biomedica presently has a consensus rating of “Hold” and an average price target of GBX 410.33.

Oxford Biomedica Stock Up 0.8%

The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48. The company has a market capitalization of £537.88 million, a PE ratio of -3.76 and a beta of 1.09. The business’s 50 day simple moving average is GBX 382.84 and its 200 day simple moving average is GBX 337.97.

Insider Transactions at Oxford Biomedica

In other news, insider Roch Doliveux acquired 67,000 shares of Oxford Biomedica stock in a transaction on Friday, August 15th. The stock was bought at an average cost of GBX 450 per share, with a total value of £301,500. Also, insider Heather Preston acquired 11,389 shares of Oxford Biomedica stock in a transaction on Tuesday, June 17th. The shares were purchased at an average cost of GBX 324 per share, with a total value of £36,900.36. 21.17% of the stock is currently owned by corporate insiders.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.